Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2021
Inspire Medical Systems (NYSE: INSP) announced preliminary, unaudited revenue results for Q4 and full year 2021. Q4 revenue is expected to be between $78.0 million and $78.4 million, marking a 70% year-over-year increase. Full year revenue is projected at $233.0 million to $233.4 million, up 102% from 2020. The company activated 81 new U.S. centers in Q4, exceeding prior guidance. Inspire also received FDA approval for a Bluetooth-enabled remote control for its therapy system. Detailed financial results will be reported on February 8, 2022.
- Q4 2021 revenue anticipated at $78.0M to $78.4M, a 70% increase year-over-year.
- Full year 2021 revenue expected to be $233.0M to $233.4M, a 102% increase from 2020.
- Activated 81 new centers in Q4, significantly exceeding the prior guidance.
- Received FDA approval for Bluetooth-enabled patient remote control, enhancing patient experience.
- None.
MINNEAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the quarter and full year ended December 31, 2021.
Preliminary, Unaudited Revenue and Recent Business Highlights:
- Revenue for the fourth quarter of 2021 is anticipated to be in the range of
$78.0 million to$78.4 million , an approximately70% increase over the same quarter last year - Revenue for full year 2021 is anticipated to be in the range of
$233.0 million to$233.4 million , an approximately102% increase over full year 2020 - Activated 81 new centers in the U.S. in the fourth quarter of 2021, bringing the total to 684 U.S. medical centers implanting Inspire therapy
- Created 16 new sales territories in the fourth quarter of 2021, bringing the total to 157 U.S. sales territories
- Received U.S. Food and Drug Administration (“FDA”) approval for the Inspire Bluetooth-enabled patient remote control
“Our team continued to perform extremely well during the fourth quarter, despite the recent and ongoing resurgence of COVID-19,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "The significant growth in our business is being driven by the enhanced patient demand for Inspire therapy and our increasing capacity at new and existing centers. While our business has demonstrated strong performance to date, the environment remains dynamic and we intend to closely monitor the impact of the ongoing COVID-19 surge on our operations as we start the new year."
"We activated 81 new U.S. implanting centers in the fourth quarter, which was well above our prior guidance of 52 to 56 new centers per quarter and is indicative of the continued substantial demand by physicians and centers for access to Inspire therapy. To further support this demand, we created 16 new U.S. sales territories in the fourth quarter,” continued Mr. Herbert. “Importantly, our robust pace in the opening of new centers includes a growing number of ASCs, which continue to increase at a higher rate than the addition of hospitals.”
“We are also pleased to announce that we recently received FDA approval of our new Bluetooth-enabled patient remote control,” added Mr. Herbert. “This approval demonstrates Inspire’s deep R&D capabilities and significantly enhances the patient experience by streamlining the sharing of device data through the Inspire Cloud.”
The preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until the Company reports its full financial results for 2021 during its earnings announcement planned for Tuesday, February 8, 2022.
Inspire previously announced that Mr. Herbert and Rick Buchholz, Inspire’s Chief Financial Officer, will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference at 3:00 p.m. ET on Thursday, Jan. 6, 2022. Last week, Inspire also announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, including a formal company presentation at 9:45 a.m. ET on Wednesday, January 12, 2022.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding fourth quarter and full year 2021 revenue results. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; the impact of the ongoing and global COVID-19 pandemic; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; and the timing or likelihood of regulatory filings and approvals. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 to be filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor & Media Contact
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
What are Inspire Medical Systems' projected revenues for Q4 2021?
How much did Inspire Medical Systems' revenue grow in 2021?
How many new medical centers did Inspire activate in Q4 2021?
What FDA approval did Inspire Medical Systems recently receive?
When will Inspire Medical Systems report its full financial results for 2021?
